Palisade Bio to Present at the 2022 BIO International Convention
June 07 2022 - 8:30AM
Palisade Bio (Nasdaq: PALI), a clinical stage
biopharmaceutical company advancing therapies for acute and chronic
gastrointestinal (GI) complications, today announced that Tom
Hallam, Ph.D., Chief Executive Officer of Palisade Bio, will
present on Monday, June 13, 2022 at 1:45 PM PT at the 2022 BIO
International Convention being held in San Diego, CA.
In addition to the presentation, management will
be available to participate in one-on-one meetings with industry
executives and qualified members of the investor community who are
registered to attend the conference. To schedule a meeting with the
Company, please reach out through the BIO partnering system.
For more information, please visit the
conference website.
About BIOBIO is the world’s largest advocacy
association representing member companies, state biotechnology
groups, academic and research institutions, and related
organizations across the United States and in 30+ countries. BIO
also produces the BIO International Convention, the world’s largest
gathering of the biotechnology industry, along with
industry-leading investor and partnering meetings held around the
world. For more information, please visit www.bio.org.
About Palisade Bio Palisade Bio is a
clinical stage biopharmaceutical company advancing therapies that
aim to aid patients suffering with acute and chronic
gastrointestinal complications stemming from post-operative
digestive enzyme damage. Palisade Bio’s innovative lead asset
LB1148, advancing toward Phase 3, is a protease inhibitor with the
potential to both reduce abdominal adhesions and help restore bowel
function following surgery. Positive data from Phase 2 trials of
LB1148 demonstrated safety and tolerability as well as a
statistically significant improvement in the return of bowel
function and a decrease in the length of stay in ICU and hospital
compared to placebo. Palisade Bio believes that its investigational
therapies have the potential to address the myriad health
conditions and complications associated with the chronic disruption
to the gastrointestinal epithelial barrier. For more information,
please go to www.palisadebio.com.
Palisade Bio Investor Relations Contact:Dawn
Hofmeisterir@palisadebio.com
Investor Relations ContactJTC Team, LLCJenene
Thomas 833-475-8247PALI@jtcir.com
Source: PalisadeBio
Palisade Bio (NASDAQ:PALI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Palisade Bio (NASDAQ:PALI)
Historical Stock Chart
From Sep 2023 to Sep 2024